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In the tumor microenvironment, TGF-β induces transdifferentiation of quiescent pericytes and related 
stromal cells into myofibroblasts that promote tumor growth and metastasis. The mechanisms governing 
myofibroblastic activation remain poorly understood, and its role in the tumor microenvironment has not 
been explored. Here, we demonstrate that IQ motif containing GTPase activating protein 1 (IQGAP1) binds 
to TGF-β receptor II (TβRII) and suppresses TβRII-mediated signaling in pericytes to prevent myofibro-
blastic differentiation in the tumor microenvironment. We found that TGF-β1 recruited IQGAP1 to TβRII 
in hepatic stellate cells (HSCs), the resident liver pericytes. Iqgap1 knockdown inhibited the targeting of 
the E3 ubiquitin ligase SMAD ubiquitination regulatory factor 1 (SMURF1) to the plasma membrane and 
TβRII ubiquitination and degradation. Thus, Iqgap1 knockdown stabilized TβRII and potentiated TGF-β1 
transdifferentiation of pericytes into myofibroblasts in vitro. Iqgap1 deficiency in HSCs promoted myo-
fibroblast activation, tumor implantation, and metastatic growth in mice via upregulation of paracrine 
signaling molecules. Additionally, we found that IQGAP1 expression was downregulated in myofibroblasts 
associated with human colorectal liver metastases. Taken together, our studies demonstrate that IQGAP1 
in the tumor microenvironment suppresses TβRII and TGF-β dependent myofibroblastic differentiation to 
constrain tumor growth.
Introduction
Cells within the tumor microenvironment are increasingly rec-
ognized as critical determinants for tumor growth (1–4). In 
this regard, TGF-β–mediated activation of pericytes and other 
mesenchymal stromal cells into tumor-associated myofibroblasts 
promotes a metastatic tumor microenvironment by increasing 
growth factor–induced angiogenesis, desmoplastic matrix, and 
tumor stiffness (2–4). Thus, mechanisms that regulate TGF-β sig-
naling in cells undergoing myofibroblastic activation are critical to 
better understanding and targeting the tumor microenvironment 
and tumor growth.
The effects of TGF-β1 on cells are mediated by the forma-
tion of a heteromeric complex on the plasma membrane that 
contains 2 receptors: TGF-β receptor I (TβRI) and TβRII (5, 6). 
Upon TGF-β1 stimulation, TβRII recruits and activates TβRI by 
phosphorylating TβRI at Glycine-Serine domains. Subsequently, 
active TβRI interacts and phosphorylates SMAD2 and SMAD3, 
which oligomerize with SMAD4. The SMAD complexes then 
translocate into the nucleus, where they collaborate with other 
transcription factors to regulate gene expression such as α-SMA 
and fibronectin, markers of myofibroblastic activation (6).
IQ motif containing GTPase activating protein 1 (IQGAP1) 
is a large protein that regulates diverse cellular functions by 
interacting with more than 90 proteins (7–10). IQGAP1 con-
trols cellular protrusions, cell shape, and motility by regulating 
dynamics of actin and microtubule (11–13). Additionally, it pro-
motes cell proliferation (14, 15), reduces cell-cell adhesions and 
increases migration (16), interacts with β-catenin, and modu-
lates β-catenin–mediated transcription (16, 17). Finally, IQGAP 
is also an MAPK scaffold (18).
IQGAP1 is currently proposed as an oncogenic protein in epi-
thelial cells that may promote tumorigenesis and metastasis (7, 
8, 14). However, Iqgap1-knockout mice exhibit an increase in late-
onset gastric hyperplasia as compared with wild-type mice (19), 
implying a complex role of IQGAP1 in tumor growth. It is con-
ceivable that IQGAP1 may exert different functions depending 
on the presence of binding partners and on the nature of cells. 
Moreover, the role of IQGAP1 in myofibroblastic activation in 
the tumor microenvironment remains entirely unexplored. 
Recent descriptions that IQGAP1 binds to receptors of VEGF, 
FGF, and EGF (13, 20, 21) and links growth factor signaling to 
the actin cytoskeleton prompted us to explore a potential role for 
IQGAP in the regulation of TGF-β receptors and their signaling 
in mesenchymal-type cells that activate into tumor-associated 
myofibroblasts, such as hepatic stellate cells (HSCs) (22), which 
are resident liver pericytes.
Here, we report that the C-terminal aa 1503–1657 region of 
IQGAP1 binds to TβRII and that IQGAP1/TβRII binding is 
required for suppressing TβRII and TGF-β signaling in primary 
human HSCs. IQGAP1 is required for the targeting of the E3 ubiq-
uitin ligase SMAD ubiquitination regulatory factor 1 (SMURF1) 
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to the plasma membrane and TβRII ubiquitination. IQGAP1 of 
HSCs suppresses myofibroblastic activation and tumor growth in 
mice and IQGAP1 in the myofibroblasts of human colorectal liver 
metastases is downregulated. Thus, our data demonstrate a new 
role for stromal IQGAP1 in the suppression of TGF-β–mediated 
activation of quiescent pericytes into myofibroblasts in the tumor 
microenvironment.
Results
IQGAP1 regulates TβRII abundance in HSCs. Since TβRII is the 
most upstream receptor that initiates TGF-β signaling, we tested 
to determine whether IQGAP1 associated with TβRII and regu-
lated TβRII in human primary HSCs (23). To this end, we first 
validated the specificity of anti-TβRII antibody by Western blot 
(WB) analyses, since the quality of commercial anti-TβRII is vari-
Figure 1
IQGAP1 interacts with TβRII and regulates its stability. (A) Left: HSCs that express TβRII-HA by retroviral transduction were transduced with 
lentiviruses encoding nontargeting shRNA (NT shRNA, control) or IQGAP1 shRNAs, and subjected to WB for TβRII. Knockdown of IQGAP1 by 3 
different shRNAs consistently upregulated TβRII protein levels. Middle: cells were transduced with retroviruses encoding YFP (control) or IQGAP1-
YFP. Overexpression of IQGAP in HSCs reduced TβRII protein. Right: endogenous TβRII protein levels increased in IQGAP1-knockdown cells. (B) 
HSCs transduced with lentiviruses encoding either NT shRNA or IQGAP1 shRNA were harvested for RNA extraction and SYBR green–based 
real-time RT-PCR. IQGAP1 knockdown did not change TβRII mRNA levels. n = 3 independent experiments. (C) IQGAP1 (red) and TβRII-HA 
(green) colocalized at the plasma membrane (arrowheads) and in intracellular vesicles (arrows) in HSCs by IF. Scale bars 20 μm. (D) Left: TβRII 
coprecipitated with IQGAP1 when IP was performed using anti-IQGAP1. Middle: IQGAP1 coprecipitated with TβRII-HA when IP was performed 
using anti-HA. Right: IQGAP1 coprecipitated with endogenous TβRII when IP was performed using anti-TβRII. Data are representative of multiple 
repeats with similar results.
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able (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI63836DS1). Using this 
antibody, we found that IQGAP1 regulates TRII abundance in 
HSCs (Figure 1A). To avoid the possibility of off-target effects 
of shRNA, multiple IQGAP1 shRNAs (Sigma-Aldrich), each 
targeting a distinct sequence of human IQGAP1, were used to 
knock down IQGAP1. In cells expressing TβRII-HA, IQGAP1 
knockdown increased TβRII protein levels and overexpression 
of IQGAP1 decreased TβRII (Figure 1A). Additionally, IQGAP1 
shRNAs also increased endogenous TβRII protein levels (Figure 
1A). Thus, Iqgap1 activity reduces levels of TβRII protein in HSCs.
IQGAP1 interacts with TβRII in HSCs. Quantitative real-time RT-
PCR revealed that IQGAP1 knockdown did not influence TβRII 
mRNA levels (Figure 1B), suggesting that IQGAP1 regulates TβRII 
stability at the posttranscriptional level, possibly by binding to 
TβRII and promoting its degradation. To test this hypothesis, we 
Figure 2
IQGAP1 C terminus aa 1503–1657 is required for binding and suppressing TβRII. (A) Top 4 rows: full-length (FL) IQGAP1 and GST-fused trun-
cated IQGAP1 proteins are shown. Bottom, GST fused truncated IQGAP1 proteins extracted from bacteria were incubated with HSC lysates 
for GST pull-down assays. Both aa 746–1657 and aa 1503–1657 of IQGAP1 bound to TβRII. Ponceau S staining depicted the purity of the 
recombinant proteins. (B) Top: after the GST tag of GST-TRII was removed by thrombin treatment, detagged TβRII was incubated with GST-fused 
IQGAP1 proteins for in vitro binding assays. Both aa 746–1657 and aa 1503–1657 of IQGAP1 bound to TβRII directly in vitro. Ponceau S staining 
depicted the purity of GST and GST-fused IQGAP1 proteins. Bottom: detagged IQGAP1 aa 746–1657 was incubated with GST or GST-TβRII for 
in vitro binding assays. GST-TβRII bound to IQGAP1 aa 746-1657 directly in vitro. aa 746–1657 instead of aa 1503–1657 of IQGAP1 was used in 
this assay because IQGAP1 antibodies could not recognize aa 1503–1657 of IQGAP1. Ponceau S staining depicted the purity of GST and GST 
fusion proteins. (C) HSCs expressing TβRII-HA were transduced with lentiviruses encoding GFP, IQGAP1-FLAG, or IQGAP1 (1-1502)-FLAG, 
and subjected to WB. In contrast with IQGAP1, IQGAP1 (1-1502) mutant lacking the TβRII binding region failed to repress TβRII protein levels. 
Densitometric ratios are shown on the bottom. All data shown represent multiple repeats with similar results.
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performed double immunofluorescence staining (IF) for IQGAP1 
and TβRII and found that IQGAP1 and TβRII colocalized at the 
peripheral plasma membrane (arrowheads, Figure 1C) and in 
endocytic vesicles (arrows, Figure 1C) in cells expressing TβRII-
HA. Coimmunoprecipitation (IP) also demonstrated that these 2 
proteins coprecipitated in HSCs expressing TβRII-HA (Figure 1D). 
Furthermore, IQGAP coprecipitated with endogenous TβRII from 
cells as well (Figure 1D). These data suggest that IQGAP1 interacts 
with TβRII in HSCs. Additionally, the interactions between these 2 
proteins occur in other cell types as well (Supplemental Figure 5).
IQGAP1 aa 1503–1657 is required for binding and suppressing TRII. 
IQGAP1 contains multiple protein-protein interacting domains 
including calponin-homology domain (CHD), poly-proline pro-
tein-protein domain (WW), IQ domain (IQ), Ras GTPase-acti-
vating protein–related domain (GRD), and RasGAP C terminus 
(RGCt) (Figure 2A and ref. 9). So we performed in vitro gluta-
thione-S-transferase (GST) pull-down assays to map the TβRII-
binding region on IQGAP1. Both aa 746–1657 and aa 1503–1657 
of IQGAP1 interacted with TβRII by GST pull-down assays (Fig-
ure 2A), suggesting that the TβRII-binding region is within the 
smaller C-terminal 1503–1657 fragment. To understand whether 
IQGAP1/TβRII binding is direct or requires adaptor proteins, we 
performed in vitro protein-binding assays by incubating detagged 
TβRII (the GST tag was removed by thrombin) with GST-fused 
IQGAP1 proteins (Figure 2B), or detagged IQGAP1 with GST-
fused TβRII (Figure 2B and Supplemental Figure 2). Both experi-
ments demonstrated a direct binding of these 2 proteins in vitro.
To test the role of aa 1503–1657 of IQGAP1 in IQGAP1/TβRII bind-
ing and TβRII abundance, we generated a IQGAP1 (1-1502) mutant 
that lacks aa 1503–1657 and found that this mutant failed to suppress 
Figure 3
IQGAP1 suppresses TGF-β–mediated activation of HSCs into myofibroblasts. (A) HSCs that were transfected with control or IQGAP1 siRNA were 
serum-starved and stimulated with TGF-β1 (5 ng/ml) or PDGF-BB (20 ng/ml). HSC activation was assessed by WB for activation markers such as 
α-SMA, fibronectin, and p-SMAD2. TGF-β1 but not PDGF-BB induced upregulation of α-SMA and fibronectin. Two different IQGAP1 siRNAs consis-
tently potentiated the effect of TGF-β1. (B) HSCs that were transfected with IQGAP1 siRNA were mixed with control cells for double IF for IQGAP1 
(green) and α-SMA (red). As compared with nontransfected HSCs (asterisks), IQGAP1 knockdown induced the formation of α-SMA–positive stress 
fibers (arrows), indicative of myofibroblastic transdifferentiation of HSCs. Scale bar: 50 μm. (C) Left: HSCs treated as described in A were subjected 
to IF for α-SMA. TGF-β1 promoted the formation of α-SMA–positive stress fibers, and this effect was potentiated by IQGAP1 siRNA. Scale bar: 
50 μm. Right: quantitative data of α-SMA IF showing that IQGAP1 knockdown significantly increased TGF-β1 activation of HSCs into myofibro-
blasts. *P < 0.05 by ANOVA. n = 7 randomly picked microscopic fields, each containing 100–200 cells. (D) HSCs that express GFP, IQGAP1-FLAG, 
or IQGAP1 (1-1502)-FLAG were stimulated with TGF-β1 and harvested for WB. IQGAP1 downregulated TβRII and inhibited HSC activation. In 
contrast, IQGAP1 (1-1502) mutant failed to suppress TβRII and TGF-β signaling. Data represent 3 independent experiments with similar results.
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TβRII protein levels in contrast with full-length IQGAP1 (Figure 2C). 
Thus, IQGAP1 aa 1503–1657 is required for IQGAP1/TβRII binding 
and suppressing TβRII. Interestingly, the C-terminal region of IQGAP 
has previously been shown to bind to β-catenin and other molecules 
contained within key signaling nodes (16), suggesting a potentially 
important biological significance of IQGAP binding with TβRII.
IQGAP1 suppresses TGF-β1–mediated activation of pericytes into myofi-
broblasts. Since receptor stability and trafficking importantly regu-
late signaling, we tested the significance of IQGAP1/TβRII bind-
ing on myofibroblastic activation of HSCs. Two different si RNAs 
(QIAGEN) were used to knock down IQGAP1 of HSCs. Cells 
were stimulated with TGF-β1 (5 ng/ml) or PDGF-BB (20 ng/ml) 
and myofibroblastic activation of HSCs was assessed by WB for 
α-SMA, fibronectin, and phospho-SMAD2 (p-SMAD2). TGF-β1 
more prominently activated HSCs as compared with PDGF-BB, as 
determined by upregulation of α-SMA, fibronectin, and p-SMAD2 
(Figure 3A). IQGAP1 knockdown by 2 distinct IQGAP1 siRNAs also 
consistently potentiated TGF-β1 activation of HSCs (Figure 3A).
Figure 4
TGF-β1 increases IQGAP1/TβRII binding, and IQGAP1 knockdown inhibits lysosomal targeting of TβRII. (A) HSCs that express TβRII-HA were 
serum starved and stimulated with TGF-β1 for indicated times. Cell lysates were subjected to IP using anti-IQGAP1, and coprecipitated TβRII 
was detected by WB. Densitometric ratios are shown on the bottom. TGF-β1 increased IQGAP1/TβRII binding. Blots represent 3 independent 
experiments. (B and C) HSCs that were serum starved and pretreated with cycloheximide (40 μg/ml) for 1 hour were incubated with TGF-β1 at 
4°C for ligand/receptor binding. After cells were incubated at 37°C for indicated times, cells were fixed for double IF for HA (green) and LAMP1 
(red). IQGAP1 knockdown significantly reduced TβRII in late endosome/lysosomes at both 30 and 60 minutes after TGF-β1 stimulation (arrow-
heads). Scale bar: 20 μm. **P < 0.01 by ANOVA. n = 6 cells each group. Data represent 3 independent experiments with identical results. (D and E) 
Cells treated as described in B and C were stained for HA and EEA-1. IQGAP1 knockdown induced the accumulation of TβRII in EEA-1–positive 
endosomes at both 30 and 60 minutes after TGF-β1 stimulation (arrows). Scale bar: 20 μm. **P < 0.01 by ANOVA. n = 6 cells each group. Data 
are representative of 3 independent repeats with identical results.
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Double IF for IQGAP1 and α-SMA demonstrated that 
IQGAP1-knockdown cells exhibited prominent α-SMA–posi-
tive stress fibers, indicative of myofibroblastic transdifferen-
tiation (arrows, Figure 3B). Quantitative data from cells stim-
ulated with TGF-β1 revealed that IQGAP1 siRNA increased 
TGF-β1–induced myofibroblastic activation by 35% (Figure 3C). 
Moreover, a SMAD siRNA targeting both SMAD2 and SMAD3 
abolished the effect of IQGAP1 siRNA on myofibroblastic acti-
vation (Supplemental Figure 3). As expected, overexpression of 
full-length IQGAP1 suppressed HSC activation and the IQGAP1 
(1-1502) mutant failed to repress HSC activation (Figure 3D). 
Taken together, these data demonstrate that by binding to 
TβRII, IQGAP1 suppresses TGF-β1/SMAD–mediated myofi-
broblastic activation of HSCs in vitro.
Figure 5
IQGAP1 knockdown inhibits TGF-β1 downregulation of TβRII, TβRII ubiquitination, and the plasma membrane targeting of SMURF1. (A) Top: HSCs 
with their cell-surface proteins prelabeled with biotin were incubated with TGF-1 for indicated times and cells were harvested for streptavidin pull-down 
and TβRII WB to determine internalized TβRII. Bottom: TβRII degradation curves generated by densitometric analysis are shown. IQGAP1 knockdown 
inhibited TGF-β1 downregulation of cell surface TβRII. Chlo, chloroquine; T½, half-life of TβRII. Data are representative of multiple independent experi-
ments. Asterisks designate a point where TβRII was down to 50%. (B) HSCs expressing TβRI-FLAG were transduced with lentiviruses encoding either 
NT shRNA or IQGAP1 shRNA, and TβRI protein levels were detected by Flag WB. IQGAP1 knockdown increased TβRI-Flag in HSCs. n = 3 experi-
ments with similar results. (C) TβRII-HA was precipitated from HSCs by IP using anti-HA; TβRII ubiquitination was detected by WB. IQGAP1 knockdown 
markedly inhibited TβRII ubiquitination. (D) Double IF for IQGAP1 (red) and SMURF1 (green) revealed that IQGAP1 and SMURF1 colocalized at the 
periphery plasma membrane in control cells (arrows, upper panels), and that IQGAP1 knockdown reduced the localization of SMURF1 at the plasma 
membrane (lower panels). Scale bar: 20 μm. (E) TβRII and SMURF1 colocalized at the peripheral plasma membrane (arrowheads, upper panels), 
and IQGAP1 knockdown reduced TβRII/SMURF1 colocalization at the plasma membrane (lower panels). Scale bar: 20 μm. (F) IQGAP1 knockdown 
reduced SMURF1 protein levels in HSCs by WB. β-actin WB was used as a loading control. n = 3 independent experiments with identical results.
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TGF-β1 stimulation increases IQGAP1/TβRII binding. TGF-β1 ligand 
induces internalization and downregulation of TβRII (24–29). 
Therefore, we tested the hypothesis that IQGAP1 may modulate 
ligand-dependent internalization and degradation of TβRII in 
HSCs. To this end, we performed IP using anti-IQGAP1 and TβRII 
WB to detect TβRII/IQGAP1 binding. As shown in Figure 4A, TGF-
β1 induced temporal increase of IQGAP1/TβRII binding, support-
ing a model whereby TGF-β1 stimulation recruits IQGAP1 to 
TβRII-containing signaling complexes, and in turn, IQGAP1 may 
modulate TβRII trafficking, degradation, and TGF-β1 signaling.
IQGAP1 knockdown inhibits lysosomal targeting of TβRII and induces 
accumulation of TβRII in the early endosomes. TβRII was localized to 
endosomes and its degradation was attenuated by lysosomal inhib-
itors (27, 28, 30–35), so we tested to determine whether IQGAP1 
knockdown could alter the trafficking of TβRII to endosomes 
and lysosomes, 2 intracellular compartments where signaling and 
receptor turnover are regulated (31, 28, 34). HSCs treated with 
TGF-β1 were subjected to double IF for HA-tagged TβRII and 
lysosomal-associated membrane protein 1 (LAMP1, late endo-
some/lysosomal marker) or early endosome antigen 1 (EEA-1, early 
endosomal marker). IQGAP1 IF confirmed IQGAP1 knockdown in 
HSCs (Supplemental Figure 4A). Double IF revealed that at both 
30 and 60 minutes after TGF-β1 stimulation, IQGAP1 knockdown 
significantly reduced TβRII reaching LAMP1-positive vesicles (late 
Figure 6
Basal activation phenotype of HSCs of Iqgap1–/– mice. (A) Left: livers of 1-year-old Iqgap1–/– and matched Iqgap1+/+ mice were subjected to H&E 
staining, and double IF for desmin (red, HSC marker) and α-SMA (green, marker of activated HSCs). Cell nuclei were counterstained by TOTO-3 
(blue). Arrows indicate colocalization of these 2 proteins. Scale bar: 50 μm. Right: quantitative data analyzed by ImageJ software revealed that 
α-SMA–positive HSCs were significantly increased in Iqgap1–/– livers compared with Iqgap1+/+ livers. **P < 0.01 by t test. (B) Left: liver samples 
as described in A were analyzed by WB for α-SMA and collagen I. Middle: densitometric analysis revealed that the average level of α-SMA or 
collagen I of Iqgap1–/– livers was significantly higher than that of Iqgap1+/+ livers. *P < 0.05; **P < 0.01 by ANOVA. Right: representative images 
of Sirius red staining are shown. Scale bar: 50 μm. (C) HSCs of mice were treated with TGF-β1 at 72 hours after isolation and harvested for WB. 
Iqgap1–/– HSCs exhibited an enhanced activation phenotype as compared with Iqgap1+/+ HSCs in vitro. n = 2 independent cell preparations using 
4 mouse livers for each prep with similar results from both cell preparations.
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endosome/lysosomes) (arrowheads, Figure 4, B and C). In control 
cells, TβRII/EEA-1 colocalization increased at 5 minutes after TGF-
β1 stimulation and decreased gradually thereafter (Figure 4, D and 
E). In IQGAP1-knockdown cells, however, TβRII/EEA-1 colocaliza-
tion continuously increased at 30 or 60 minutes after TGF-β1 stim-
ulation (Figure 4, D and E), suggesting that IQGAP1 knockdown 
induces accumulation of TβRII in the early endosomes.
IQGAP1 knockdown inhibits lysosomal and proteasomal degradation of 
TβRII. We next used biotinylation of cell-surface proteins to ana-
lyze TGF-β1 downregulation of cell-surface TβRII in control and 
IQGAP1-knockdown cells. In control cells, TGF-β1 downregu-
lated cell-surface TβRII in a time-dependent manner; TβRII half-
life was about 44 minutes (Figure 5A). In IQGAP1-knockdown 
cells, however, it increased to about 63 minutes (Figure 5A), con-
sistent with the observation that IQGAP1 knockdown inhibited 
TGF-β1–mediated lysosomal targeting of TβRII. Additionally, 
both chloroquine (Chlo, lysosomal inhibitor) and MG132 (pro-
teasomal inhibitor) were able to partially prevent TβRII down-
regulation (Figure 5A). Furthermore, IQGAP1 knockdown also 
inhibited TGF-β1 downregulation of total cellular TβRII protein 
in cells that were pretreated with cycloheximide (Supplemental 
Figure 4B). Thus, these data support a model that IQGAP1 binds 
to TβRII and promotes TGF-β1–mediated lysosomal and protea-
somal degradation of TβRII.
IQGAP1 knockdown inhibits TβRII ubiquitination. Since TGF-β 
stimulation induces the formation of complexes that contain 
TβRII and TβRI (5, 6), we compared TβRI protein levels in con-
trol and IQGAP1-knockdown HSCs. Similar to TβRII, IQGAP1 
knockdown also increased exogenously expressed TβRI-FLAG in 
HSCs (Figure 5B), further supporting the model whereby IQGAP1 
is recruited to the TGF-β receptor complexes where it promotes 
the degradation of TGF-β receptors.
Ubiquitination is an important signal for plasma membrane 
receptor internalization, multivesicular body sorting, and degra-
dation (36). TβRII is also subjected to ubiquitin modification sim-
ilarly to TβRI (33, 37), so we tested to determine whether IQGAP1 
Figure 7
IQGAP1 deficiency in the liver promotes myofibroblastic activation and lung liver metastases in mice. (A) Depiction of portal vein implantation 
of LLCs into the livers of mice. (B) Left: average tumor weight of Iqgap1–/– livers was significantly higher than that of Iqgap1+/+ livers at 10 days 
after tumor implantation. *P < 0.05 by t test. Right: representative photographs of liver and liver metastases (mets) of mice are shown. (C) WB 
on isolated liver metastases revealed that the average level of α-SMA or TβRII of the liver metastases of Iqgap1–/– mice was significantly higher 
than that of Iqgap1+/+ mice. GAPDH WB was used as a protein loading control. *P < 0.05; **P < 0.01 by ANOVA. (D) Representative images of 
α-SMA IF (green) and H&E staining revealing more tumor-associated myofibroblasts in the liver metastases of Iqgap1–/– mice as compared with 
Iqgap1+/+ mice. Cell nuclei were counterstained by TOTO-3 (blue). MFs, tumor-associated myofibroblasts. Scale bar: 50 μM.
Downloaded on July  2, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/63836
research article
1146 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 3   March 2013
knockdown influenced the ubiquitination of TβRII. To this end, 
TβRII-HA was precipitated from HSCs expressing TβRII-HA, and 
TβRII ubiquitination was detected by ubiquitin WB. As shown in 
Figure 5C, IQGAP1 knockdown markedly reduced the ubiquitina-
tion of TβRII in HSCs.
IQGAP1 is required for the targeting of SMURF1 to the plasma mem-
brane. The turnover of TGF-β receptors is regulated by the E3 ubiq-
uitin ligases such as SMURF1 and SMURF2, which interact and 
ubiquitinate TGF-β receptors at the plasma membrane (27, 38, 
39). Based on this model, we tested to determine whether IQGAP1 
knockdown influenced the subcellular localization of SMURF1. 
Consistent with the concept that SMURF1 localizes at the cellular 
protrusions (40), we found that in control HSCs, SMURF1 local-
ized at the peripheral plasma membrane in addition to the nucleus 
and cytoplasm (arrows, Figure 5D). IQGAP1 knockdown reduced 
SMURF1 at the plasma membrane (Figure 5D) and SMURF1/
TβRII colocalization at the plasma membrane (Figure 5E). Inter-
estingly, we also found that IQGAP1 knockdown reduced the 
total protein levels of SMURF1 (Figure 5F), suggesting a role of 
IQGAP1 in the regulation of SMURF1 stability. Thus, IQGAP1 
promotes the ubiquitination and degradation of TβRII in HSCs 
possibly by at least 2 different mechanisms: (a) directing SMURF1 
to the plasma membrane where SMURF1 interacts with the TGF-β 
receptor complexes and (b) stabilizing SMURF1 protein levels.
Evidence for a basal activation phenotype of HSCs of Iqgap1–/– mice. To 
determine whether IQGAP1 suppresses HSC activation in vivo, 
we isolated livers from 1-year-old Iqgap1+/+ and Iqgap1–/– mice for 
IF and WB. As compared with matched Iqgap1+/+ livers, double IF 
revealed that Iqgap1–/– livers contained significantly more HSCs 
that were double-positive for α-SMA and desmin, another marker 
of HSCs (refs. 41, 42, and Figure 6A). WB confirmed this mor-
phologic observation (Figure 6B). Additionally, Iqgap1–/– livers 
contained significantly more collagen I, as detected by WB (Fig-
ure 6B). Next, we isolated HSCs from mice and treated them with 
TGF-β1 for 24 hours and found that Iqgap1–/– HSCs exhibited an 
enhanced activation phenotype in vitro as compared with Iqgap1+/+ 
HSCs (Figure 6C). Thus, these data support that IQGAP1 of HSCs 
suppresses HSC activation in vivo.
IQGAP1 deficiency in the tumor microenvironment promotes myofi-
broblastic activation and liver metastatic growth. The basal activation 
phenotype of HSCs of Iqgap1–/– mice led us to test if Iqgap1–/– liv-
ers promoted liver metastatic growth. Lewis lung carcinoma cells 
(LLCs), a mouse cancer cell line that is widely used in metastasis 
studies, were implanted into the livers of Iqgap1+/+ and Iqgap1–/– 
mice by portal vein injection (Figure 7A). This study allowed us to 
study the specific effect of IQGAP1 depletion in the liver micro-
environment on liver metastatic growth, since the implanted 
LLCs harbored intact IQGAP1 protein. Upon necropsy, we found 
Figure 8
IQGAP1 deficiency in the liver promotes colorectal liver metastases in mice. (A) 2 × 106 MC38 mouse colorectal cancer cells were implanted into 
the livers of Iqgap1–/– and matched Iqgap1+/+ mice by portal vein injection, and mouse survival was analyzed by GraphPad Prism 5 software. 
**P < 0.01 by ANOVA. (B and C) MC38 cells tagged by firefly luciferase were injected into the livers of mice and bioluminescence of MC38 cells 
was quantitated by in vivo xenogen imaging at different days after tumor implantation. Data were analyzed by the GraphPad Prism 5 software, 
and representative images are shown. *P < 0.05 by ANOVA.
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Figure 9
IQGAP1-knockdown HSCs promote colorectal tumor implantation and growth in HSC/tumor coimplantation model. (A) 0.5 × 106 HT-29 
human colorectal tumor cells were mixed with 0.5 × 106 control HSCs (HSC-NTshRNA) or 0.5 × 106 IQGAP1-knockdown HSCs (HSC-
IQGAP1shRNA), respectively, and coimplanted into nude mice via subcutaneous injection. Tumor nodules were measured by a caliper at 
different days after implantation, and data were analyzed by the GraphPad Prism 5 software. IQGAP1-knockdown HSCs exhibited a greater 
tumor-promoting effect as compared with control HSCs. *P < 0.05 by ANOVA. (B) 0.5 × 106 HT-29 cells tagged by firefly luciferase were 
mixed with 0.5 × 106 control HSCs or 0.5 × 106 IQGAP1-knockdown HSCs, respectively, and coimplanted into nude mice via subcutaneous 
injection. Bioluminescence of HT-29 cells was quantitated by in vivo xenogen imaging at indicated days after tumor implantation, and data 
were analyzed by GraphPad Prism 5 software. Imaging of representative mice and quantitative data are shown. IQGAP1-knockdown HSCs 
promoted the implantation of HT-29 cells in mice as compared with control HSCs. *P < 0.05 by ANOVA. (C) HSCs tagged by firefly luciferase 
were implanted into nude mice alone or with HT-29 tumor cells via subcutaneous injection. Bioluminescence of HSCs was quantitated by 
in vivo xenogen imaging at different days after implantation. Data are representative of 6 mice with consistent results. HSCs were able to 
survive up to 23 days in mice after HSC/tumor coimplantation.
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that the average tumor weight in the liver of Iqgap1–/– mice was 4 
times greater than that of Iqgap1+/+ mice at 10 days after implan-
tation (Figure 7B) (Iqgap1+/+: 183.8 ± 72 mg/liver; Iqgap1–/–: 832.7 
± 255 mg/liver; P < 0.05), indicating that IQGAP1 deficiency in 
the tumor microenvironment promotes liver metastatic growth in 
mice. Since Iqgap1–/– T cells do not exhibit reduced cytolytic func-
tion as compared with Iqgap1+/+ T cells (43), this enhanced liver 
metastatic growth phenotype of Iqgap1–/– mice is unlikely to be due 
to IQGAP1 depletion in T cells.
Liver metastases isolated from the livers were subjected to WB 
and IF for α-SMA (maker of tumor-associated myofibroblasts) 
and PECAM-1/CD31 (marker of endothelial cells). As revealed by 
WB, the average level of α-SMA protein in the liver metastases of 
Iqgap1–/– mice was more than 10 times higher than that of Iqgap1+/+ 
mice (P < 0.01) (Figure 7C). Consistent with our previously depict-
ed in vitro data, the average level of TβRII protein in the liver 
metastases of Iqgap1–/– mice was more than 3 times higher than 
that of Iqgap1+/+ mice (P < 0.05) (Figure 7C). In contrast, PECAM-1/ 
CD31 protein levels were comparable in liver metastases of both 
groups (Figure 7C). IF confirmed that the liver metastases of 
Iqgap1–/– mice indeed contained more α-SMA–positive tumor-
associated myofibroblasts (Figure 7D) and that endothelial cell 
densities were comparable in both groups (Supplemental Figure 
6). Taken together, this liver metastasis study demonstrates that 
IQGAP1 in mesenchymal cells residing in the tumor microenvi-
ronment suppresses TβRII protein levels, myofibroblastic activa-
tion in vivo, and liver metastatic growth.
IQGAP1 deficiency in the tumor microenvironment promotes colorectal 
liver metastases. Since gastrointestinal cancers including colorectal 
and pancreatic cancers show a preference for liver metastasis, we 
next implanted MC38 mouse colorectal cancer cells into the livers of 
Iqgap1+/+ and Iqgap1–/– mice. Similar to LLCs, MC38 cells implanted, 
quickly multiplied, and occupied mouse liver in vivo. The median 
survival of Iqgap1+/+ mice was about 19 days, and it was shortened to 
13 days for Iqgap1–/– mice (P < 0.01), confirming an enhanced colorec-
tal liver metastatic growth phenotype in Iqgap1–/– mice (Figure 8A). 
Next, MC38 cells expressing firefly luciferase were implanted to 
determine whether IQGAP1 deficiency in the tumor microenviron-
ment promoted tumor implantation into the liver. In vivo xenogen 
imaging that measured bioluminescence of MC38 cells revealed that 
at day 3 after tumor implantation, significantly more MC38 cells 
were detected in Iqgap1–/– livers than in Iqgap1+/+ livers (Figure 8, B 
and C). These data indicate that Iqgap1–/– livers promote colorectal 
tumor implantation possibly by protecting the tumor cells from 
anoikis. This hypothesis was pursued as shown below.
IQGAP1-knockdown HSCs promote colorectal tumor implantation and 
growth in mice. In addition to HSCs, other liver-resident cells, such as 
fibroblasts, bone marrow–derived fibrocytes, hepatocytes, or chol-
angiocytes after epithelial-mesenchymal transition, are postulated 
to play a role in liver fibrosis (44). Therefore, we next performed 
an HSC/tumor cell coimplantation study to define a specific and 
selective role of HSCs for myofibroblastic activation and tumor 
growth. HT-29 human colorectal cancer cells that were mixed with 
an equal number of control HSCs (transduced with NT shRNA) 
or IQGAP1-knockdown HSCs (transduced with IQGAP1 shRNA) 
were implanted into nude mice via subcutaneous injection. Tumor 
growth curves generated by monitoring mice carefully for 17 days 
revealed that both control and IQGAP1-knockdown HSCs accel-
erated HT-29 tumor growth in mice (Figure 9A). Furthermore, 
IQGAP1-knockdown HSCs exerted a greater effect on promoting 
HT-29 tumor growth as compared with control HSCs (Figure 9A). 
Since HT-29 cells were tagged by firefly luciferase before implanta-
tion, in vivo xenogen imaging was performed to study the role of 
IQGAP1-knockdown HSCs in HT-29 implantation in mice (Figure 
9B). At day 5 after implantation, the HT-29/HSC-IQGAP1 shRNA 
coimplantation group exhibited the highest level of HT-29 biolu-
minescence as compared with other groups (Figure 9B). A detailed 
analysis revealed that in the HT-29–only implantation group, 
HT-29 bioluminescence decreased continuously at days 3 and 5 
after implantation, possibly representing anoikis of HT-29 cells, 
and that coimplantation of either control or IQGAP1-knockdown 
HSCs increased HT-29 bioluminescence at these time points (Figure 
9B). Furthermore, coimplantation of IQGAP1-knockdown HSCs 
resulted in the greatest increase of HT-29 bioluminescence (Figure 
9B). Thus, this HSC/tumor cell coimplantation study supports the 
concept that IQGAP1-knockdown HSCs promote colorectal tumor 
growth by promoting the implantation of tumor cells in mice.
IQGAP1 knockdown in HSCs promotes TβRII protein levels and myo-
fibroblastic activation of HSCs in mice. To understand whether coim-
planted HSCs indeed transdifferentiated into tumor-associated 
myofibroblasts in mice, we performed in vivo xenogen imaging to 
determine the survival of the coimplanted HSCs. HSCs tagged with 
firefly luciferase were implanted into nude mice alone (control) 
or with HT-29 cells via subcutaneous injection. In the HSC-only 
implantation group, bioluminescence of HSCs started to decrease 
continuously at day 6 to an undetectable level at day 14 after implan-
tation (Figure 9C). In the HSC/tumor cell coimplantation group, 
however, it increased again at day 13 and remained at a detectable 
level at day 23 after implantation (Figure 9C; data are representative 
of 6 mice with consistent results). These data indicate that HSCs are 
able to survive up to 23 days after HSC/tumor cell coimplantation 
and that this prolonged survival of HSCs is dependent on tumor 
cells. Since the coimplanted HSCs were also tagged by TβRII-HA 
fusion proteins, we performed double IF on isolated tumor nodules 
to visualize the coimplanted HSCs. As revealed by double IF for HA 
tag and α-SMA, most HA-positive cells in the tumor nodules also 
expressed α-SMA (arrows, Figure 10A), suggesting that these coim-
planted HSCs indeed transformed into tumor-associated myofibro-
blasts. WB revealed that the average level of TβRII-HA or α-SMA in 
tumors arising from IQGAP1-knockdown HSC coimplantation was 
significantly higher than that in tumors arising from control HSC 
coimplantation (Figure 10B). This finding was confirmed by IF for 
HA (Figure 10C) and α-SMA as well (Figure 10D). Thus, this HSC/
tumor cell coimplantation study demonstrates a suppressive role 
of HSC IQGAP1 for TβRII protein, myofibroblastic activation, and 
tumor growth in vivo.
HSCs are activated into tumor-associated myofibroblasts of liver metasta-
ses. To determine whether HSCs in the liver indeed transdifferenti-
ate into the tumor-associated myofibroblasts of liver metastases, 
we performed portal vein implantation of L3.6 human gastroin-
testinal cancer cells into the liver of SCID mice and isolated xeno-
grafts for IF. Stem121 is an antibody that has been extensively 
used to detect the engraftment of human cells transplanted into 
mice owing to its ability to detect a cytoplasmic protein specific to 
human origin cells. Double IF for α-SMA and Stem121 revealed 
that the stroma (S) of liver metastases identified by α-SMA–positive 
staining were negative for Stem121 and that tumor cells (T) were 
positive for Stem121 and negative for α-SMA (Figure 11A). These 
data indicate that these tumor-associated myofibroblasts were 
not derived from the implanted human cancer cells, but rather, 
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further, we performed double IF for α-SMA and desmin on liver 
sections containing L3.6 micrometastases and found that a frac-
tion of HSCs adjacent to the L3.6 tumor cells were positive for both 
α-SMA and desmin (arrowheads, Figure 11C). Additionally, these 
activated HSCs were negative for Stem121 (arrows, Figure 11D). 
from cells residing in the host mouse liver. To identify their origin, 
immunohistochemistry for α-SMA and desmin was perform on 
adjacent sections of the liver metastases. As shown in Figure 11B, 
some of these stromal cells were indeed positive for desmin, sug-
gesting that they may have an HSC origin. To test this hypothesis 
Figure 10
IQGAP1 knockdown in HSCs promotes TβRII levels, myofibroblastic activation of HSCs in a HSC/tumor coimplantation model. (A) HSCs express-
ing TβRII-HA were mixed with HT-29 tumor cells and coimplanted into nude mice via subcutaneous injection. Tumor nodules were subjected to IF 
for HA (green) and α-SMA (red) and H&E staining. Cells positive for both HA and α-SMA were detected in the tumor nodules (arrows). Cell nuclei 
were counterstained by TOTO-3 (blue). S, stroma; T, tumor cells. Scale bar: 50 μm. (B) Tumor nodules were subjected to WB and densitometric 
analysis. The average level of TβRII-HA or α-SMA in tumors arising from HT-29/HSC-IQGAP1shRNA coimplantation was significantly higher 
than that in tumors arising from HT-29/HSC-NTshRNA coimplantation. **P < 0.01 by ANOVA. (C) Representative HA IF (green) and H&E staining 
revealing more TβRII-HA–positive tumor-associated myofibroblasts in tumor nodules arising from HT-29/HSC-IQGAP1shRNA coimplantation as 
compared with tumors arising from HT-29/HSC-NTshRNA coimplantation. Cell nuclei were counterstained by TOTO-3 (blue). Scale bar: 50 μm. 
(D) Tumor nodules were subjected to α-SMA IF (green), H&E staining, and quantitative analysis. The average α-SMA IF density in tumors aris-
ing from HT-29/HSC-IQGAP1shRNA coimplantation was significantly higher than that in tumors from HT-29/HSC-NTshRNA coimplantation. 
*P < 0.05 by t test. Scale bar: 100 μm.
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and Boyden chamber assay were performed to test their effect on 
tumor cell proliferation and migration. As expected, the condi-
tioned medium of control HSCs promoted the proliferation and 
migration of HT-29 (Figure 12, A and B) and LLCs (Supplemen-
tal Figure 7) as compared with basal medium. Importantly, the 
conditioned medium of IQGAP1-knockdown HSCs exhibited 
a greater stimulatory effect on tumor cells than that of control 
HSCs (Figure 12, A and B, and Supplemental Figure 7). As detect-
ed by DAPI staining and WB for PARP cleavage, an early marker 
of cell apoptosis, these conditioned media protected MC38 cells 
from apoptosis in cell suspension culture and anoikis assays, and 
the conditioned media of IQGAP1-knockdown HSCs conferred a 
greater protection to MC38 cells (Figure 12C). These data support 
It is interesting that L3.6 cells were also positive for desmin, with 
desmin representing one of a panel of diagnostic markers for cer-
tain tumors (45, 46). Taken together, these data provide evidence 
for transactivation of liver-resident HSCs into the tumor-associated 
myofibroblasts using an experimental liver metastasis model.
IQGAP1-knockdown HSCs confer a greater stimulatory effect on 
proliferation, migration, and survival of tumor cells. To understand 
mechanisms by which IQGAP1-knockdown HSCs promoted liver 
metastatic growth in mice, conditioned medium were collected 
from control and IQGAP1-knockdown HSCs and incubated with 
tumor cells. MTS-based (with MTS indicating 3-[4,5-dimeth-
ylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-
2H-tetrazolium, inner salt) nonradioactive cell proliferation assay 
Figure 11
HSCs are activated into tumor-associated myofibroblasts of liver metastases. (A) L3.6 human gastrointestinal cancer cells were implanted into 
the livers of SCID mice by portal vein injection. Established liver metastases were isolated for H&E staining and double IF for Stem121 (green), 
a specific marker of human engraftments, and α-SMA (red). Tumor-associated myofibroblasts of liver metastases were negative for Stem121 
(arrows). Cell nuclei were counterstained by TOTO-3 (blue). Scale bar: 100 μm. (B) Adjacent sections of L3.6 liver metastases were subjected to 
H&E staining, immunostaining for Stem121, α-SMA, or desmin. Some tumor-associated myofibroblasts were positive for desmin (arrows). Scale 
bar: 50 μm. (C) Liver sections containing L3.6 micrometastases were subjected to H&E staining and double IF for α-SMA (green) and desmin 
(red). Some HSCs at the sinusoids adjacent to L3.6 tumor cells were activated to express α-SMA (arrowheads). Cell nuclei were counterstained 
by TOTO-3 (blue). Scale bars: 50 μm. (D) Adjacent sections of micrometastases shown in C were subjected to double IF for Stem 121 and α-SMA 
or desmin. The activated HSCs adjacent to the tumor cells were negative for Stem 121 (arrows). Cell nuclei were counterstained by TOTO-3 
(blue). Scale bar: 50 μm.
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finding is very interesting, since both SDF-1/CXCL12 and HGF 
play a central role in tumor metastasis and angiogenesis (47, 48) 
and SDF-1/CXCL12 has been identified as a chemokine that regu-
lates organ-specific metastasis in various cancers (49–51).
IQGAP1 in the myofibroblasts of patient colorectal liver metastases is down-
regulated. Double IF for IQGAP1 and α-SMA was performed on liver 
biopsies of patients with colorectal cancers to determine IQGAP1 
expression status in the stroma of established liver metastases. Liver 
biopsies of 29 colorectal cancer patients were obtained from a Mayo 
Clinic tissue collection. This patient cohort was 55% male and 45% 
that IQGAP1 deficiency in activated HSCs may confer a great-
er stimulatory effect on the growth and survival of tumor cells 
through the release of soluble factors.
Next, we isolated mRNAs from control and IQGAP1-knockdown 
HSCs for real-time quantitative RT-PCR analyses for paracrine 
cellular growth and motility factors, including TGF-β1, PDGF 
ligands, SDF-1/CXCL12, and HGF. Although the mRNA levels of 
TGF-β1 and PDGF ligands were not changed by IQGAP1 knock-
down, the transcripts of SDF-1/CXCL12 and HGF were significant-
ly increased by IQGAP1 knockdown in HSCs (Figure 12D). This 
Figure 12
IQGAP1-knockdown HSCs promote the proliferation, migration, and survival of tumor cells. (A) Conditioned medium collected from control and 
IQGAP1-knockdown HSCs were used as a growth stimulant for HT-29 in nonradioactive cell proliferation assays. Conditioned medium of IQGAP1-
knockdown HSCs promoted the proliferation of HT-29 cells as compared with that of control shRNA–transduced HSCs. CM, conditioned medium. 
*P < 0.05 by ANOVA; n = 3 repeats with similar results. (B) Conditioned medium collected as described in A were used as a chemoattractant 
for HT-29 in Boyden chamber assays. Conditioned medium of IQGAP1-knockdown HSCs promoted HT-29 migration as compared with that of 
control shRNA–transduced HSCs. *P < 0.05 by ANOVA; n = 3 repeats with similar results. Scale bar: 100 μm. (C) MC38 cells were suspended in 
basal medium or conditioned medium as described in A and seeded onto polyhydroxyethylmethacrylate (poly-HEMA) precoated culture dishes. 
After cells were incubated for 24 hours with gentle shaking, anoikis was assessed by DAPI staining of unfixed cells (top) and WB for PARP cleav-
age (lower right). Conditioned medium of IQGAP1-knockdown HSCs protected MC38 cells from anoikis as compared with that of control HSCs. 
*P < 0.05 by ANOVA. n = 3 repeats. Scale bar: 50 μm. (D) Control and IQGAP1-knockdown HSCs were harvested for RNA extraction and SYBR 
green–based real-time RT-PCR for SDF-1/CXCL12 and HGF. The mRNA level of SDF-1/CXCL12 or HGF was significantly increased by IQGAP1 
knockdown in HSCs. *P < 0.05 by t test; n = 3 independent experiments.
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microenvironment, we next tested the hypothesis that when 
tumor cells intermingled with HSCs in the liver, tumor-derived 
factors might act on HSCs to reduce IQGAP1 expression of HSCs. 
To this end, conditioned medium of HT-29, MC38, and CT26 
colorectal cancer cells were used to treat HSCs. As detected by 
WB, each conditioned medium tested indeed moderately reduced 
the IQGAP1 level of HSCs as compared with basal culture medi-
um (Figure 13D). Furthermore, TGF-β1 (5 ng/ml) recapitu-
lated the effect of the conditioned medium (Figure 13D), while 
PDGF-BB (20 ng/ml) did not (Supplemental Figure 8). Interest-
ingly, IQGAP1 does not couple with TβRII for degradation after 
TGF-β1 stimulation, as shown in Figure 5A and Supplemental 
Figure 4B, indicating that IQGAP1 is downregulated by TGF-β1 
through an alternative mechanism. Thus, that tumor-derived fac-
tors induced downregulation of IQGAP1 in the tumor-associated 
myofibroblasts may be important for the initiation and growth 
characteristics of colorectal liver metastasis in patients.
female, and all were clinically diagnosed with metastatic colorectal 
cancer (Supplemental Table 1). The age of patients was from 32 to 90 
years old, with a median of 63 years old. Their primary colon cancers 
originated from different colonic sites including ascending, trans-
verse, descending, sigmoid colon, and rectum. After double IF for 
α-SMA and IQGAP1, IQGAP1 IF intensity in the myofibroblasts of 
the liver metastases was quantitated and compared with that in the 
myofibroblasts of matched control liver (Figure 13, A–C, and Supple-
mental Table 1). Out of 29 patients analyzed, 24 patients displayed 
varying degrees of reduction of IQGAP1 protein in the myofibro-
blasts of their liver metastases as compared with IQGAP1 expres-
sion levels observed in activated HSCs and portal myofibroblasts of 
the adjacent nontumorous control liver (Figure 13, A and C). This 
reduction was statistically significant in this cohort as detected by 
Student’s t test (P < 0.01) (Figure 13B).
Since metastatic growth in the liver is largely dependent on 
the communication between tumor cells and the hepatic tumor 
Figure 13
IQGAP1 in the myofibroblasts of human colorectal liver metastases is downregulated. (A) Double IF for IQGAP1 and α-SMA was performed 
on liver biopsies of 29 patients with metastatic colorectal cancer. IQGAP1 IF intensities in the myofibroblasts of liver metastases and matched 
control liver were quantitated by ImageJ software. MFs, myofibroblasts. (B) Box and whisker plots revealing that IQGAP1 in the myofibroblasts 
of patient colorectal liver metastases was significantly lower than that of the matched livers. **P < 0.01 by t test. (C) IF and H&E staining of a 
representative patient are shown. Cell nuclei were counterstained by TOTO-3 (blue). Scale bar: 100 μm. (D) Conditioned media collected from 
HT-29, CT26, and MC38 colorectal cancer cells were incubated with HSCs for 24 hours. IQGAP1 protein levels of HSCs were determined by WB 
and densitometric analyses. Conditioned medium of colorectal tumor cells downregulated IQGAP1 of HSCs. TGF-β1 (5 ng/ml) recapitulated the 
effect of the conditioned medium. Data represent multiple experiments with similar results.
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mote tumor implantation, tumor angiogenesis, and tumor pro-
gression (4). Additionally, they regulate ECM turnover and sup-
press the antitumor immune response, creating a prometastatic 
microenvironment for tumor cells (4). Besides TGF-β, PDGF also 
activates HSCs by stimulating the proliferation and migration of 
HSCs/myofibroblasts. Imatinib mesylate (Gleevec), sunitinib, and 
sorafenib are recently approved anti-cancer drugs that target tyro-
sine kinases, such as the PDGF receptor, as well as intracellular 
kinases downstream from the TGF-β receptor, such as c-Abl (4, 
23). Thus, these anti-cancer drugs and new compounds under 
development that are currently being tested in clinical trials may 
have implications in preventing and reducing liver metastases 
through the effect on the hepatic tumor microenvironment (2, 4).
SMURFs/SMAD7 complexes antagonize TGF-β signaling by at 
least 2 different mechanisms: (a) preventing TβRI-induced phos-
phorylation of receptor regulated Smads (R-Smads) by forming 
a complex with TβRI and (b) promoting the ubiquitination and 
degradation of TGF-β receptor complexes (27, 38). IQGAP1 is 
required for the targeting of SMURF1 to the peripheral plasma 
membrane where TβRII and SMURF1 colocalize, but we do not 
know if IQGAP1 binds to SMURF1 directly or not. Since SMAD7 
recruits SMURF2 to the TGF-β receptors (27, 33), it is possible 
that IQGAP1 regulation of SMURF1 localization requires SMAD7. 
The accumulation of TβRII in the early endosomes of IQGAP1-
knockdown cells suggests that IQGAP1 knockdown may block 
the sorting of TβRII from the early endosomes to late endosomal/
lysosomal compartments for degradation. Alternatively, since 
TβRII is internalized via either clathrin-coated pits or clathrin-
independent caveolar/lipid-raft (28), IQGAP1 knockdown may 
sequester TβRII from the caveolar/lipid-raft and thereby shift 
TβRII into the clathrin-dependent endocytic pathway, similar to a 
TβRII-trafficking model previously proposed (28, 32). Thus, while 
IQGAP has recently been implicated in exocytosis regulation (53), 
our study demonstrates what we believe is a new role for IQGAP1 
in the regulation of endocytosis and degradation of receptors.
In summary, we demonstrate here a role for IQGAP1 in 
mesenchymal cells residing in the tumor microenvironment as 
compared with that previously described in epithelial cells, where-
by IQGAP in the tumor microenvironment suppresses myofibro-
blastic activation and, in turn, is frequently downregulated in 
human colorectal liver metastases by the tumor-derived factors. 
Differentiation of roles of IQGAP1 in tumor cells and the tumor 
Discussion
Prior studies have demonstrated that IQGAP1 functions as an 
oncogenic protein in epithelial cells by virtue of its ability to inter-
act with and modulate specific proteins with well-defined tumori-
genic roles, such as Rac1, E-cadherin, β-catenin, EGF receptor and 
mTOR (7, 14, 15, 21). However, mice lacking IQGAP1 developed 
significantly more gastric hyperplasia and polyps at an older age 
(19). Interestingly, we demonstrate here that IQGAP1 suppresses 
the TGF-β1–mediated activation of HSCs into myofibroblasts in 
vitro and in vivo. IQGAP1 is recruited to TGF-β receptor complexes 
with the C-terminal aa 1503–1657 of IQGAP1 mediating IQGAP1/
TβRII interaction (Figure 14). Through scaffolding TβRII and 
SMURF1, IQGAP1 promotes the ubiquitination and degradation 
of the TGF-β receptors, thus suppressing TβRII and the TGF-β1–
mediated myofibroblastic transactivation of HSCs in the tumor 
microenvironment. Tumor-derived paracrine factors including 
TGF-β1, however, are able to partially remove this suppression of 
IQGAP1 by downregulating IQGAP1 of HSCs (Figure 14). Our 
study highlights bidirectional interactions between tumor cells 
and the tumor microenvironment for liver metastatic growth and 
supports an amplification loop whereby tumor cells downregulate 
HSC IQGAP and this in turn increases TGF-β1 signaling in HSCs 
that leads to transformation of HSCs into tumor-associated myo-
fibroblasts. Tumor-associated myofibroblasts transdifferentiated 
from IQGAP1-deficient HSCs in turn further promote liver meta-
static growth by upregulating paracrine cellular growth and motil-
ity factors such as SDF-1/CXCL12 and HGF (Figure 14).
During the evolution of cancer, tumor suppressor genes are 
often inactivated by various mechanisms, such as loss of hetero-
zygosity, mutations, or epigenetic alterations (52). In this study, 
we found that IQGAP1 in the myofibroblasts of colorectal liver 
metastases is frequently downregulated in patients, akin to the 
well-characterized tumor suppressors in epithelial tumor cells. 
Mechanisms of such downregulation by tumor-derived paracrine 
factors including TGF-β1 are not well understood but may be a 
result of epigenetic changes. Our findings that IQGAP1 deficiency 
in HSCs promotes myofibroblastic activation and liver metastatic 
growth may be clinically important for human cancer, since they 
highlight the bidirectional interactions between tumor cells and 
HSCs, in particular the activated HSCs/myofibroblasts, as a poten-
tial therapeutic target for liver metastasis (2, 4). The activated 
HSCs are a rich source of growth factors and cytokines that pro-
Figure 14
IQGAP1 of HSCs suppresses TGF-β activation of HSCs into myofi-
broblasts, and this effect is counterbalanced by tumor-derived factors. 
The C-terminal aa 1503–1657 of IQGAP1 binds to TβRII in a manner 
that is enhanced by TGF-β stimulation. IQGAP1 recruited to the TGF-β 
receptor complexes promotes SMURF1/TβRII colocalization at the 
plasma membrane, TβRII ubiquitination, and lysosomal and protea-
somal degradation of TβRII. Thus IQGAP1 regulates TβRII degrada-
tion and cellular protein abundance. IQGAP1 binding and repression of 
TβRII suppresses activation of HSCs into myofibroblasts, thus limiting 
liver metastatic growth. Tumor-derived factors including TGF-β1, how-
ever, are able to downregulate IQGAP1 of HSCs, thereby amplifying 
the TGF-β1 activation of HSCs into tumor-associated myofibroblasts, 
which in turn, further promote liver metastatic growth by upregulating 
paracrine factors such as SDF-1/CXCL12 and HGF.
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2% formalin (in PIPE buffer, pH 6.95) (56). Fluorescence confocal images 
were captured by a LSM 5 Pascal Laser Scanning Microscope (Zeiss) using 
a ×63 or ×25 lens and Laser Scanning Microscope LSM PASCAL software 
(version 4.2 SP1).
To quantitate TβRII colocalization with EEA-1 or LAMP1, representative 
cells after IF were captured by a ×63 lens. After splitting merged pictures 
into single channels, the total number of vesicles positive for TβRII-HA in 
a cell was obtained by counting the vesicles that were green. The number 
of vesicles positive for both TβRII and EEA-1 or LAMP1 was obtained by 
counting vesicles that were yellow in merged pictures. The following equa-
tion was used: percentage of TβRII-HA colocalized with EEA-1 or LAMP1 = 
the number of yellow vesicles/the number of green vesicles × 100%. At least 
6 representative cells per group were selected for analysis. To quantitate 
α-SMA IF on tissue sections, at least 3 microscopic fields per slide were 
selected randomly for analysis. Confocal images were converted to gray 
scale, and histograms were generated by ImageJ software (NIH). α-SMA IF 
counts were presented by the total frequencies of the gray and white pixels.
In situ cross-linking, IP, and WB analysis. In situ cross-linking was performed 
by incubating cells in 1 mM cross-linker dithiobis[succinimidylpropionate] 
(DSP) at room temperature for 30 minutes followed by 0.2 M glycine for 
15 minutes to quench excess DSP. Cells were then harvested and lysed in 
a buffer containing 1% NP-40, 0.1% SDS, 0.25% deoxycholate acid, and 
protease inhibitors (Roche Diagnostics). Then, 1–2 μg antibody and 30 μl 
slurry of protein G–conjugated sepharose beads were used to pull down the 
protein complexes from HSC lysates (200–500 μg per sample). After beads 
were washed 4 times, precipitated proteins were eluted with Laemmli sam-
ple buffer (Bio-Rad) and loaded onto PAGE gels for WB. Immunoblotting 
was done as we previously described (55). Densitometry was performed by 
the ImageJ software (NIH).
GST pull-down and in vitro protein-binding assay. GST or GST fused truncat-
ed IQGAP1 proteins were purified from E. coli (BL21 DE3) by glutathione 
sepharose beads. GST pull-down assays were performed as described pre-
viously (57). For in vitro binding assays, the GST tag was first removed 
by thrombin, and detagged proteins were purified and recovered by the 
Thrombin Cleavage Capture Kit (Novagen, 69022). The detagged proteins 
were then incubated with GST alone or GST-fused proteins for binding 
assays as previously described (58).
Quantitation of TβRII degradation by biotinylation approach. Biotin labeling 
of cell-surface proteins and streptavidin-agarose pull-down were used to 
determine the degradation rate of cell surface TβRII by TGF-β1. In brief, 
serum-starved HSCs were cooled on ice to stop receptor endocytosis; bio-
tin was then added into culture medium and incubated with cells at 4°C 
for 30 minutes (EZ-Link Sulfo-NHS-Biotin, 21217; Thermo Scientific). 
After free biotin was removed, TGF-β1 (final concentration is 5 ng/ml) 
was added and incubated with cells at 4°C for 30 minutes for TGF-β1/
receptor binding. Cells were harvested after they were incubated at 37°C 
for various times. Streptavidin-agarose pull-down (S1638; Sigma-Aldrich) 
followed by WB for TβRII was used to quantitate TβRII that was internal-
ized and spared from degradation.
Quantitative RT-PCR. Total RNA was extracted from HSCs using RNeasy 
kit (QIAGEN). Reverse transcription was performed using T15-oligo-
nucleotide and Superscript RNase H-reverse transcriptase (Invitrogen). 
Amplification reactions were performed using a SYBR Green PCR Master 
Mix (Applied Biosystems) in an Applied Biosystems 7500 Real Time PCR 
System instrument. GAPDH was used in the same reaction of all samples 
as an internal control. mRNAs of interest were normalized to GAPDH 
mRNA and shown as the fold change. Primers were as follows: TβRII, TGT-
GTGACTTTGGGCTTTCC and GACATCGGTCTGCTTGAAGG; SDF-1/
CXCL12, CCTTCCCTAACACTGGTT and TTGACCCGAAGCTAAAGTGG; 
HGF, CCCTGTAGCCTTCTCCTTGA and CGAGGCCATGGTGCTATACT.
stromal cells could help design better strategies to manipulate 
tumor cells, the tumor microenvironment, and tumor/stromal 
interactions in the process of tumor progression and metastasis. 
Furthermore, new and mechanistic information pertaining to the 
cell biological effects of IQGAP1 on TGF-β signaling should pro-
vide new insights relevant to a variety of diseases associated with 
desmoplasia and fibrosis.
Methods
Cell lines, expression vectors, and reagents. Human primary HSCs were pur-
chased from ScienCell Research laboratories and cultured in DMEM 
supplemented with 10% fetal bovine serum and antibiotics (penicillin and 
streptomycin) (23, 54). HSCs with passage 5–10 were used in this study. 
LLCs and HT-29 human and CT26 mouse colon cancer cells were from 
ATCC. MC38 mouse colorectal cancer cells were provided by Steven A. 
Rosenberg (National Cancer Institute, Bethesda, Maryland, USA) and L3.6 
cells were provided by Raul Urrutia (GI Research Unit, Mayo Clinic).
Retroviral vectors pMMP-TβRII-HA, pMMP-TβRI-FLAG, and pMMP-
IQGAP1-YFP and lentiviral vectors expressing IQGAP1-FLAG or IQGAP1 
(1-1502)-FLAG were generated by inserting a cDNA into pMMP or pSIN_
BX-IRES lentiviral vector. All constructs were confirmed by sequencing and 
WB analysis. Retroviruses were generated and harvested by transfecting 
293T cells with plasmids as previously described (55). Lentiviruses were 
generated by ViraPower Lentiviral Expression Systems (Invitrogen). Viral 
transduction was done by incubating cells with viral supernatant (25%) 
supplemented with polybrene (8 μg/ml) overnight at 37°C. Further experi-
ments were performed at 48–96 hours after viral transduction.
hTGF-β1 was from R & D Systems (100-B). Antibodies used include anti-
IQGAP1 (H-109) (sc-10792; Santa Cruz Biotechnology Inc.), anti-IQGAP1 
(ab33542; Abcam), anti-TβRII (K105) (3713; Cell Signaling), anti-TβRII 
(E-6) (sc-17792; Santa Cruz Biotechnology Inc.), anti-EEA1 (610456; BD 
Transduction Laboratory), anti-LAMP1 (H4A3) (sc-20011; Santa Cruz 
Biotechnology Inc.), anti–α-SMA (A5228, Sigma-Aldrich), anti-fibronec-
tin (610077; BD Transduction Laboratory), anti–p-SMAD2 (S465/467) 
(3101; Cell Signaling), anti-SMAD2/3 (3102; Cell Signaling), anti-HA 
(12CA5) (Roche Diagnostics), anti-HA (c29F4) (3724; Cell Signaling), anti-
DYKDDDDK (FLAG tag) (2368; Cell Signaling), anti-ubiquitin (P4D1) 
(sc-8017; Santa Cruz Biotechnology Inc.), anti–PECAM-1/CD31 (M-20) 
(sc-1506; Santa Cruz Biotechnology Inc.), anti-PARP (556494; BD Biosci-
ences — Pharmingen), anti-desmin (ab32362; Abcam), Stem121 antibody 
(AB-121; StemCells Inc.), anti-collagen I (600-401-103; Rockland), anti–β-
actin (A5441; Sigma-Aldrich), and anti-GAPDH (G8140; US Biological).
Protein knockdown by shRNA or siRNA. Lentiviral vectors encoding distinct 
IQGAP1 shRNAs were purchased from Sigma-Aldrich (NM_003870.2-
6211s1c1, NM_003870.2-3950s1c1, and NM_003870.2-569s1c1). Len-
tiviruses were generated by ViraPower Lentiviral Expression Systems 
(Invitrogen). SiRNAs were transfected into HSCs by Oligofectamine 
Reagent (Invitrogen). Control siRNA (SI03650318), IQGAP1 siRNA-1 
(S100057043), IQGAP1 siRNA-2 (S100057050), IQGAP1 siRNA-3 
(S102655268), and SMAD siRNA (S102757496) were from QIAGEN. All 
assays were performed at 72–96 hours after siRNA transfection.
IF, confocal microscopy, and quantification. HSCs that were fixed with 3% 
paraformaldehyde and permeabilized by 0.2% Triton X-100 were incu-
bated with specific primary antibodies and Alexa Fluor–conjugated IgG 
(Invitrogen) was used for secondary detection. To stain mouse or human 
biopsies, frozen tissues were sectioned at 7 μm using a Leica cryostat. For 
double IF for TβRII and EEA-1 or LAMP1, HSCs that were serum starved 
and pretreated with cycloheximide (40 μg/ml) were incubated with TGF-
β1 (5 ng/ml) at 4°C for 30 minutes for TGF-β1/receptor binding. Cells 
were then incubated at 37°C for various times before they were fixed with 
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of a Boyden chamber (NeuroProbe). Basal medium and conditioned medium 
were used as chemoattractants in the bottom wells. Four hours later, cells that 
had migrated to the lower surface were stained with DAPI and cell images 
were captured from random microscopic fields by a fluorescence microscope. 
Cells were then counted by Metamorph software (Molecular Devices) (59). 
Cell proliferation assay was determined by a CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay kit (Promega) according to the manu-
facturer’s instruction. In brief, 2,500 cells that were suspended in 100 μl of 
conditioned medium were seeded into each well of a 96-culture plate. After 
cells were incubated at 37°C for different times, MTS and PMS reagents were 
added and cell numbers were presented by the absorbance at 490 nm using 
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Tumor cell anoikis assay. Tumor cell suspension culture and anoikis assays 
were performed as we described previously (55). In brief, 0.2 × 106 MC38 
cells were seeded into a 6-well cell-culture dish coated with polyhydroxy-
ethylmethacrylate (poly-HEMA) previously. Cells were then cultured in 
basal medium (control) or conditioned medium collected from control or 
IQGAP1-knockdown HSCs. Cells were cultured under a standard condi-
tion with gentle shaking for 24 hours. Apoptosis of cells was assessed by 
morphological analysis of cell nuclei DAPI staining (5 μg/ml) and by WB 
analysis for PARP cleavage, an early marker of cell apoptosis.
Statistics. All data are presented as mean ± SEM. Two-tailed Student’s 
t test or ANOVA was used to evaluate statistical significance using Graph-
Pad Prism 5 software (GraphPad Software, Inc). P < 0.05 was considered 
statistically significant.
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Experimental liver metastasis and HSC/tumor cell coimplantation model. 
Iqgap1-knockout mouse line was generated by André Bernards (19) and 
maintained in 129/BL6 mixed background. Eight-week-old littermate 
Iqgap1+/+ and Iqgap1–/– mice were used as recipients for the experimental 
liver metastasis study. Eight-week-old male SCID mice (01S11; Frederick 
National Lab) were also used as transplantation recipients. 1 × 106 LLCs, 
1 × 106 L3.6 pancreatic cancer cells, or 2 × 106 MC38 mouse colorectal 
cancer cells were implanted into each mouse liver via portal vein injection 
as we previously described (55). Eight-week-old male nude mice (01B74; 
Frederick National Lab) were used as recipients for HSC/tumor cell coim-
plantation study. In brief, 0.5 × 106 HT-29 human colorectal cancer cells 
(50 μl in PBS) were mixed with 0.5 × 106 human HSCs with or without 
IQGAP1 knockdown (50 μl in PBS) and were coinjected into the lower 
flank of nude mice using a 0.5-cc syringe and a 27-gauge needle subcu-
taneously. Tumor diameters were measured by a caliper at different days 
after implantation. Tumor volume was calculated by the following for-
mula: tumor volume = (width)2 × length/2 (59).
In vivo xenogen imaging of mice. Cells expressing firefly luciferase were 
implanted into mice via portal vein injection or subcutaneous injection. 
On different days after tumor implantation, mice were injected with 
150 μl D-luciferin (15 mg/ml) via intraperitoneal injection and anesthe-
tized by isoflurane. In vivo xenogen imaging was performed using a Xeno-
gen IVIS 200 machine (Caliper Life Sciences) and bioluminescence was 
quantitated using Living Image software (Caliper Life Sciences) (60).
Quantification of IQGAP1 expression in human colorectal liver metastases. Spec-
imens containing liver metastases and matched peritumoral liver samples 
(control) were subjected to double IF for α-SMA and IQGAP1. IF confocal 
images were acquired by a LSM 5 Pascal Laser Scanning Microscope (Zeiss) 
using a ×25 lens. Two sets of images, one from liver metastasis regions and 
the other from matched liver, were taken from each patient for quanti-
fication using ImageJ software (NIH). In brief, regions of interest (ROIs) 
were chosen randomly at areas positive for α-SMA (rich in myofibroblasts) 
from the liver metastases and control liver, respectively, and integrated 
density (not affected by area) of IQGAP1 IF was calculated. More than 3 
images were selected randomly from each section and at least 3 ROIs were 
chosen from each confocal image for analysis. The mean of multiple ROIs 
that were selected from a patient was calculated and data were exported to 
Microsoft Excel for further calculations. Finally, data generated from the 
liver metastases were compared with the matched control liver samples and 
a ratio was calculated for each patient.
Boyden chamber assay and cell proliferation assay. Conditioned medium was 
collected from serum-starved HSCs that were transduced with either NT 
shRNA or IQGAP1 shRNA. To assess the effect of the conditioned medium 
on tumor cell migration, 15,000 tumor cells were seeded into each upper well 
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